WO2009144088A2 - Vaccine for protection against lawsonia intracellulars - Google Patents
Vaccine for protection against lawsonia intracellulars Download PDFInfo
- Publication number
- WO2009144088A2 WO2009144088A2 PCT/EP2009/054516 EP2009054516W WO2009144088A2 WO 2009144088 A2 WO2009144088 A2 WO 2009144088A2 EP 2009054516 W EP2009054516 W EP 2009054516W WO 2009144088 A2 WO2009144088 A2 WO 2009144088A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- lawsonia intracellularis
- cells
- carbohydrate
- live
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Definitions
- the present invention pertains to a vaccine for protection against an infection with Lawsonia intracellularis, a vaccine in this sense being a composition that at least provides a decrease in a negative influence of the infection with Lawsonia intracellularis, such negative influence being e.g. tissue damage and/or clincal signs such as decreased weight gain, diarrhea, etc.
- Proliferative enteropathy also called enteritis or ileitis
- enteritis in many animals, in particular pigs, presents a clinical sign and pathological syndrome with mucosal hyperplasia of immature crypt epithelial cells, primarily in the terminal ileum.
- Other sites of the intestines that can be affected include the jejunum, caecum and colon.
- Weanling and young adult pigs are principally affected with typical clinical manifestation of rapid weight loss and dehydration.
- Natural clinical disease in pigs occurs worldwide. The disease is consistently associated with the presence of intracellular curved bacteria, presently known as Lawsonia intracellularis.
- oral vaccination against Lawsonia intracellularis has shown to be an economically efficient measure to control Ileitis and to allow a better exploitation of the genetic growth potential of the pig (Porcine Proliferative Enteropathy Technical manual 3.0, July 2006; available from Boehringer Ingelheim).
- oral rather than parenteral vaccination will reduce the transmission of blood-borne infections such as PRRS via multi-use needles and the reduction of injection site reactions and needles retained in carcasses. It will reduce animal and human stresses, time, labour costs and effort compared to individual vaccination (McOrist: "Ileitis - One Pathogen, Several Diseases" at the IPVS Ileitis Symposium in Hamburg, June 28 th , 2004).
- the advantage of an attenuated live vaccine approach is that the efficacy of immunity is usually relatively good, as the host's immune system is exposed to all the antigenic properties of the organism in a more "natural" manner.
- intracellular bacterial agents such as Lawsonia intracellularis
- the live attenuated vaccine approach is believed to offer the best available protection for vaccinated animals, due to a full and appropriate T cell based immune response. This is in contrast with the variable to poor immunity associated with subunit or killed vaccine types for intracellular bacteria.
- obligate intracellular bacteria such as Lawsonia intracellularis or the Chlamydia sp, which cause pathogenic infections within the mucosa.
- a non-live carbohydrate containing composition the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with Lawsonia intracellularis, the vaccine being in a form suitable for systemic administration.
- Systemic administration can be performed e.g. by administering the antigens into muscle tissue (intramuscular), into the dermis (intradermal), underneath the skin (subcutaneous), underneath the mucosa (submucosal), in the veins (intravenous) etc.
- muscle tissue Intramuscular
- dermis Intradermal
- mucosa submucosal
- veins Intravenous
- an important advantage of the present non-live vaccine is that it is an inherent safety when compared to a live vaccine.
- the carbohydrate containing composition can be used to manufacture a vaccine by using art-known methods that basically comprise admixing the antigenic carbohydrate containing composition (or a composition derived therefrom, such as a dilution or concentrate of the original composition or an extract, one or more purified components etc.) with a pharmaceutically acceptable carrier, e.g. a liquid carrier such as (optionally buffered) water or a solid carrier such as commonly used to obtain freeze- dried vaccines.
- a pharmaceutically acceptable carrier e.g. a liquid carrier such as (optionally buffered) water or a solid carrier such as commonly used to obtain freeze- dried vaccines.
- manufacturing can take place in an industrial environment but also, the antigens could be mixed with the other vaccine constituents in situ (i.e. at a veterinaries', a farm etc.), e.g. (immediately) preceding the actual administration to an animal.
- the antigens should be present in an immunologically effective amount, i.e. in an amount capable of stimulating the immune system of the target animal sufficiently to at least reduce the negative effects of a post-vaccination challenge with wild-type micro-organisms.
- adjuvants e.g., ethylene glycol
- stabilisers e.g., ethylene glycol
- viscosity modifiers e.g., viscosity modifiers
- other substances such as adjuvants, stabilisers, viscosity modifiers or other components are added depending on the intended use or required properties of the vaccine.
- systemic vaccination many forms are suitable, in particular liquid formulations (with dissolved, emulsified or suspended antigens) but also solid formulations such as implants or an intermediate form such as a solid carrier for the antigen suspended in a liquid.
- Systemic vaccination, in particular parenteral vaccination (i.e. not trough the alimentary canal), and suitable (physical) forms of vaccines for systemic vaccination have been known for more than
- EP 843 818 (Boehringer Ingelheim) describes the intramuscular administration of a killed vaccine (paragraph [01 15] in combination with paragraph [01 19]). In par [01 15] it is stated that the bacteria were killed by storing them at 4°C at normal atmospheric conditions. As is commonly known however, under such conditions Lawsonia intracellularis bacteria survive. Thus, this document does not teach the subject matter of the present invention. It is also noted that a carbohydrate containing composition, wherein the carbohydrate is also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, is known from Kroll et al. (Clinical and Diagnostic Laboratory Immunology, June 2005, 693-699). However, this composition is used for diagnostics. It has not been tested as a protective antigen for reasons as stated here-above.
- the carbohydrate containing composition is material resulting from the killing of Lawsonia intracellularis bacteria. It has been found that a very convenient way of providing the carbohydrate for use according to the present invention is to simply kill Lawsonia intracellularis cells and use the material resulting from that as a source for the carbohydrate. To extract the carbohydrate from living cells could in theory also be done (analogous to the creation of living ghost cells by removing the cell wall) but requires more sophisticated and thus more expensive techniques. The material as a whole could be used, e.g. a suspension of whole cells or a lysate of Lawsonia intracellularis cells, or one could purify or even isolate the carbohydrate out of the material. This method can be performed by using relatively simple art-known techniques.
- the carbohydrate containing composition contains whole cells of killed Lawsonia intracellularis bacteria This has proven to be the most convenient way to provide the carbohydrate as an antigen in the vaccine. Besides, the efficacy of the vaccine is even further increased, possibly since this way of offering the antigen to the immune system of the target animal better mimics the natural environment of the carbohydrate.
- the vaccine comprises an oil in water adjuvant containing oil droplets of sub-micrometer size.
- an adjuvant is a non-specific immunostimulating agent.
- each substance that is able to favor or amplify a particular process in the cascade of immunological events, ultimately leading to a better immunological response i.e. the integrated bodily response to an antigen, in particular one mediated by lymphocytes and typically involving recognition of antigens by specific antibodies or previously sensitized lymphocytes
- an adjuvant can be defined as an adjuvant. It has been shown that using an oil in water adjuvant containing oil droplets of sub-micrometer size provides a very good protection against Lawsonia intracellularis.
- the adjuvant comprises droplets of biodegradable oil and droplets of mineral oil, the droplets of biodegradable oil having an average size that differs from the average size of the droplets of mineral oil. It has been shown that the use of a mixture of biodegradable oil and mineral oil provides very good results with regard to efficacy and safety. In addition to this, stability of the composition is very high, which is an important economic advantage. The stability has proven to be very good, in particular when the average (volume weighed) size of either the biodegradable oil droplets or the mineral droplets is below 500 nm (preferably around 400 nm).
- the vaccine further comprises antigens of Mycoplasma hyopneumoniae and Porcine circo virus.
- Hitherto combination vaccines of Lawsonia intracellularis have been suggested in the prior art. However, not many of such combinations have actually been tested for efficacy. The reason for this is that it is generally understood that combination of antigens with antigens of Lawsonia intracellularis can only lead to successful protection if the Lawsonia antigens are provided as live (attenuated) cells. In this respect, we refer to WO 2005/011731 , which also suggests all kinds of combination vaccines based on Lawsonia intracellularis.
- Example 1 describes a method to obtain a substantially protein free carbohydrate containing composition and a vaccine that is made by using this composition.
- Example 2 describes an experiment wherein a second vaccine according to the present invention is compared with the vaccine currently on the market and an experimental vaccine comprising subunit proteins of Lawsonia intracellularis.
- Example 3 describes an experiment wherein two different vaccines according to the present invention are compared with the vaccine currently on the market.
- Example 4 describes an experiment wherein a dosage affect of a vaccine according to the invention is established.
- a method is described to obtain a substantially protein free carbohydrate composition associated with the outer cell membrane of Lawsonia intracellularis cells and a vaccine that can be made using this composition.
- a carbohydrate is an organic compound that contains carbon, hydrogen, and oxygen, usually in the ratio 1 :2:1.
- carbohydrates are sugars (saccharides), starches, celluloses, and gums. Usually they serve as a major energy source in the diet of animals.
- Lawsonia intracellularis is a gram negative bacterium, which thus contains an outer membrane that is not constructed solely of phospholipid and protein, but also contains carbohydrates, in particular polysaccharide (usually polysaccharides such as lipopolysaccharide, lipo-oligosaccharde, or even non-lipo polysaccharides).
- the resulting material which is a carbohydrate containing composition, in particular containing the carbohydrates as present in live Lawsonia intracellularis bacteria in association with their outer cell membrane (see paragraph below), was stored at 2-8°C until further use.
- the composition was formulated in Diluvac forte adjuvant.
- This adjuvant (see also EP 0 382 271 ) comprises 7.5 weight percent vitamine E acetate droplets with an average volume weighted size of approximately 400 nm, suspended in water and stabilized with 0.5 weight percent of Tween 80 (polyoxyethylene sorbitan mono-oleate).
- Each milliliter vaccine contained material that had been extracted from 1.2E8 Lawsonia intracellularis cells. IMMUNE PRECIPITATION OF LAWSONIA CARBOHYDRATE ANTIGENS
- this fraction contains carbohydrates (namely: all protein is lysed, and sonified DNA fractions will not show as a clear band in a Silver stain), and that the carbohydrates are in association with (i.e. forming part of or being bound to) the outer cell membrane of Lawsonia intracellularis (namely: the MoAb's raised against this fraction also recognized whole Lawsonia intracellularis cells).
- the carbohydrate composition is believed to comprise polysaccharide(s).
- This experiment was conducted to test a convenient way to formulate the carbohydrate antigen in a vaccine, viz. via a killed whole cell (also known as bacterin). As controls the commercially available vaccine Enterisol® ileitis and an experimental subunit vaccine comprising protein subunits were used. Next to this unvaccinated animals were used as a control.
- An inactivated whole cell vaccine was made as follows. Live Lawsonia intracellularis cells derived from the intestines of pigs with PPE were gathered. The cells were inactivated with 0.01% BPL (beta-propiolactone). The resulting material, which inherently is a non-live carbohydrate containing composition in the sense of the present invention (in particular since it contains the carbohydrates as present in live Lawsonia intracellularis bacteria in association with their outer cell membrane), was formulated in Diluvac forte adjuvant (see Example 1 ) at a concentration of approximately 2.8x10 8 cells per ml vaccine.
- the subunit vaccine contained recombinant P1/2 and P4 as known from EP 1219711 (the 19/21 and 37 kDa proteins respectively), and the recombinant proteins expressed by genes 5074, 4320 and 5464 as described in WO2005/070958.
- the proteins were formulated in Diluvac forte adjuvant.
- the vaccine contained approximately 50 ⁇ grams of each proteins per milliliter.
- a faeces sample (gram quantities) and a serum blood sample of each pig was taken and stored frozen until testing.
- the faeces samples were tested in a quantitative PCR (Q-PCR) test and expressed as the logarithm of the amount found in picograms (pg).
- Serum samples were tested in the commonly applied IFT test (Immuno fluorescent antibody test to detect antibodies against whole Lawsonia intracellularis cells in the serum,). For histological scoring a relevant sample of the ileum was taken, fixed in 4% buffered formalin, routinely embedded and cut into slides.
- HE stain Hematoxylin-Eosin
- IHC stain anti- Lawsonia intracellularis monoclonal antobidies
- Table 3 Mean histology score for the ileum.
- This experiment was conducted to test a vaccine comprising a carbohydrate containing composition as antigen.
- a second vaccine to be tested contained in addition to killed whole cells of Lawsonia intracellularis, antigens of Mycoplasma hyopneumoniae and Porcine circo virus (the "combi" vaccine).
- the commercially available Enterisol® ileitis vaccine was used.
- unvaccinated animals were used as a second control.
- the vaccine based on a substantially protein free carbohydrate containing composition was obtained as described under Example 1.
- the experimental combi vaccine contained inactivated Lawsonia intracellularis whole cell antigen (see Example 2 for the used method of providing the inactivated bacteria) at a level of 1.7x10 8 cells/ml.
- inactivated PCV-2 antigen (20 ⁇ grams of the ORF 2 encoded protein of PCV 2 per ml; the protein being expressed in a baculo virus expression system as commonly known in the art, e.g. as described in WO 2007/028823
- inactivated Mycoplasma hyopneumoniae antigen the same antigen in the same dose as is known from the commercially available vaccine Porcilis Mhyo®, obtainable from Intervet, Boxmeer, The Netherlands).
- Adjuvant "X" The antigens were formulated in a twin emulsion adjuvant "X".
- This adjuvant is a mixture of 5 volume parts of adjuvant "A” and 1 volume part of adjuvant "B”.
- Adjuvant "A” consists of mineral oil droplets with an approximate average (volume weighed) size around 1 ⁇ m, stabilised with Tween 80 in water.
- Adjuvant "A” comprises 25 weight % of the mineral oil and 1 weight % of the Tween. Rest is water.
- Adjuvant “B” consists of droplets of biodegradable vitame E acetate with an approximate average (volume weighed) size of 400 nm, stabilised also with Tween 80.
- the adjuvant "B” comprises 15 weight% of vitamine E acetate and 6 weight % of Tween 80, rest is water.
- Group 4 Sixty-four 3-day-old SPF piglets were used. The pigs were allotted to four groups of 14 piglets and one group of 8 piglets (Group 4). Group 1 was vaccinated intramuscularly at 3 days of age with 2 ml of the combi vaccine, followed by a second vaccination at 25 days of age. Group 2 was vaccinated intramuscularly once with 2 ml combi vaccine at 25 days of age. Group 3 was vaccinated orally with 2 ml Enterisol® ileitis (Boehringer Ingelheim) at 25 days of age according to prescriptions. Group 4 was vaccinated intramusculary at 3 and 25 days of age with 2 ml of the non-protein carbohydrate vaccine.
- Group 5 was left unvaccinated as a challenge control group.
- All pigs were challenged orally with homogenized infected mucosa. Subsequently all pigs were daily observed for clinical signs of Porcine Proliferative Enteropathy (PPE).
- PPE Porcine Proliferative Enteropathy
- serum blood and faeces samples were taken from the pigs for serology and PCR respectively.
- 68 days of age all pigs were euthanized and post-mortem examined. The ileum was examined histologically.
- Histology scores of group 1 and 4 were significantly lower compared to those of groups 3 and 5 (p ⁇ 0.05, two-sided Mann-Whitney U test (see table 6).
- the number of pigs with confirmed PPE were 2/13 in group 1 , 6/12 in group 2, 12/14 in group 3, 2/7 in group 4 and 12/14 in the control group 5.
- Groups 1 and 4 had a significantly lower incidence of PPE compared to groups 3 and 5 (p ⁇ 0.05, two-sided Fischers' exact test).
- Table 6 Mean histology score for the ileum.
- adjuvants containing small droplets and no or little mineral oil confer good protection against ileitis, in particular when compared to the commercially available vaccine Enterisol® Ileitis, the dose of antigens could be lowered. This could be done by administering less vaccine (down to e.g. 0.2 ml, suitable for e.g. intradermal application), or decreasing the antigenic content of the vaccine. Based on analogues in vaccine technology it is believed that with an antigenic dose (per vaccination) derived from or containing 1 E7 cells, in particular 2.5E7 cells or higher, still comparable or even better results can be obtained than with the current commercially available vaccine.
- the combination vaccine provided titres for Mhyo and PCV antibodies to a level comparable with the levels obtainable with commercially available single vaccines, it is understood that the combination vaccine also provides protection against Mycoplasma hyopneumoniae and Porcine circo virus.
- Example 4 Given the fact that the combination vaccine provided titres for Mhyo and PCV antibodies to a level comparable with the levels obtainable with commercially available single vaccines, it is understood that the combination vaccine also provides protection against Mycoplasma hyopneumoniae and Porcine circo virus.
- This experiment was conducted to establish a dosage affect of a vaccine according to the invention. Also in this experiment unvaccinated animals were used as a control.
- Inactivated whole cell vaccines were made as indicated in example 2.
- the antigenic material was formulated in Diluvac forte adjuvant at a concentration of approximately 2.0 x10 8 cells per ml vaccine, respectively 5.0X10 7 and 1.25X10 7 cells per ml vaccine.
- Sixty 3-day-old SPF piglets were used. The pigs were allotted to four groups of 15 pigs each. The piglets of groups 1 , 2 and 3 were vaccinated intramuscularly (in the neck) at 3-day old and 25-day-old with 2 ml of the vaccine each time. Group 4 was left as unvaccinated control. At 46-day-old all pigs were challenged orally with Lawsonia bacteria as indicated under example 2.
- Group 1 showed an average total weight gain of approximately 5350 grams.
- Group 2 this was 5150 grams.
- Group 3 showed a weight gain of about 4250 grams, whereas Group 4 showed a weight gain of 4550 grams.
- Histology scores The total histology score and the number of animals which were confirmed to have PPE are depicted in table 9.
- Table 9 Mean histology score for the ileum.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL09753743T PL2268308T3 (en) | 2008-04-18 | 2009-04-16 | Vaccine for protection against lawsonia intracellulars |
DK09753743.5T DK2268308T3 (en) | 2008-04-18 | 2009-04-16 | VACCINE FOR PROTECTION AGAINST LAWSONIA INTRACELLULARIS |
RU2010146927/15A RU2523561C2 (en) | 2008-04-18 | 2009-04-16 | Vaccine against lawsonia intracellularis |
EP09753743.5A EP2268308B1 (en) | 2008-04-18 | 2009-04-16 | Vaccine for protection against lawsonia intracellulars |
CN2009801136792A CN102006883A (en) | 2008-04-18 | 2009-04-16 | Vaccine for protection against lawsonia intracellulars |
ES09753743.5T ES2666671T3 (en) | 2008-04-18 | 2009-04-16 | Vaccine for protection against Lawsonia intracellularis |
CA2717969A CA2717969C (en) | 2008-04-18 | 2009-04-16 | Vaccine for protection against lawsonia intracellularis |
EP20167953.7A EP3708186A1 (en) | 2008-04-18 | 2009-04-16 | Vaccine for protection against lawsonia intracellularis |
EP18154850.4A EP3351267B1 (en) | 2008-04-18 | 2009-04-16 | Vaccine for protection against lawsonia intracellularis |
BR122019000869-8A BR122019000869B1 (en) | 2008-04-18 | 2009-04-16 | COMPOSITION OF INACTIVATED WHOLE CELLS OF LAWSONIA INTRACELLULARIS CONTAINING CARBOHYDRATE |
PL18154850T PL3351267T3 (en) | 2008-04-18 | 2009-04-16 | Vaccine for protection against lawsonia intracellularis |
US12/988,083 US20110033496A1 (en) | 2008-04-18 | 2009-04-16 | Vaccine for protection against lawsonia intracellulars |
JP2011504462A JP6026106B2 (en) | 2008-04-18 | 2009-04-16 | Vaccines for protection against Lawsonia intracellularis |
BRPI0909769-4A BRPI0909769B1 (en) | 2008-04-18 | 2009-04-16 | USE OF A CARBOHYDRATE-CONTAINING INACTIVATED WHOLE CELL COMPOSITION OF LAWSONIA INTRACELLULARIS |
US13/657,210 US8597662B2 (en) | 2008-04-18 | 2012-10-22 | Vaccine for protection against Lawsonia intracellularis |
US13/944,234 US9198963B2 (en) | 2008-04-18 | 2013-07-17 | Vaccine for protection against Lawsonia intracellularis |
FR21C1002C FR21C1002I1 (en) | 2008-04-18 | 2021-01-18 | VACCINE FOR PROTECTION AGAINST LAWSONIA INTRACELLULARIS |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4616108P | 2008-04-18 | 2008-04-18 | |
EP08154764 | 2008-04-18 | ||
US61/046,161 | 2008-04-18 | ||
EP08154764.8 | 2008-04-18 | ||
US11175608P | 2008-11-06 | 2008-11-06 | |
EP08105738 | 2008-11-06 | ||
EP08105738.2 | 2008-11-06 | ||
US61/111,756 | 2008-11-06 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/988,083 A-371-Of-International US20110033496A1 (en) | 2008-04-18 | 2009-04-16 | Vaccine for protection against lawsonia intracellulars |
US13/657,210 Division US8597662B2 (en) | 2008-04-18 | 2012-10-22 | Vaccine for protection against Lawsonia intracellularis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009144088A2 true WO2009144088A2 (en) | 2009-12-03 |
WO2009144088A3 WO2009144088A3 (en) | 2010-05-06 |
Family
ID=41212183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/054516 WO2009144088A2 (en) | 2008-04-18 | 2009-04-16 | Vaccine for protection against lawsonia intracellulars |
Country Status (13)
Country | Link |
---|---|
US (3) | US20110033496A1 (en) |
EP (3) | EP2268308B1 (en) |
JP (2) | JP6026106B2 (en) |
CN (1) | CN102006883A (en) |
BR (1) | BR122019000869B1 (en) |
CA (1) | CA2717969C (en) |
DK (2) | DK3351267T3 (en) |
ES (1) | ES2666671T3 (en) |
FR (1) | FR21C1002I1 (en) |
HU (2) | HUE038294T2 (en) |
PL (2) | PL3351267T3 (en) |
TW (1) | TWI551295B (en) |
WO (1) | WO2009144088A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8530223B2 (en) | 2009-11-09 | 2013-09-10 | Intervet International B.V. | Method to grow Lawsonia intracellularis bacteria in persistently infected McCoy cells |
WO2015082458A1 (en) | 2013-12-03 | 2015-06-11 | Intervet International B.V. | Vaccine against porcine circo virus type 2 |
WO2015082457A1 (en) | 2013-12-03 | 2015-06-11 | Intervet International B.V. | Vaccine against lawsonia intracellularis and porcine circovirus 2 |
WO2016124620A1 (en) | 2015-02-04 | 2016-08-11 | Intervet International B.V. | A vaccine for use against subclinical lawsonia infection in a pig |
WO2016124623A1 (en) | 2015-02-04 | 2016-08-11 | Intervet International B.V. | A vaccine for use against subclinical lawsonia infection in a pig |
KR101837768B1 (en) | 2011-05-25 | 2018-03-12 | 건국대학교 산학협력단 | Protein for dianosing porcine proliferative enteritis and application thereof |
RU2655615C1 (en) * | 2013-12-03 | 2018-05-29 | Интервет Интернэшнл Б.В. | Swine vaccine against prrs and lawsonia intracellularis |
WO2019110481A1 (en) | 2017-12-04 | 2019-06-13 | Intervet International B.V. | Vaccination with replicon particles and oil adjuvant |
WO2019166362A1 (en) | 2018-02-28 | 2019-09-06 | Boehringer Ingelheim Vetmedica Gmbh | Method for reducing skatole and/or indole in animals |
WO2023073640A1 (en) | 2021-11-01 | 2023-05-04 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic gel compositions |
WO2023072805A1 (en) | 2021-10-25 | 2023-05-04 | Intervet International B.V. | A vaccine for the protection of piglets against swine influenza a virus infection |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI551295B (en) * | 2008-04-18 | 2016-10-01 | 英特威特國際股份有限公司 | Vaccine for protection against lawsonia intracellularis |
HUE059657T2 (en) * | 2015-10-22 | 2022-12-28 | Intervet Int Bv | A vaccine to protect an mda positive animal against a disorder arising from an infection with lawsonia intracellularis |
JP6655414B2 (en) | 2016-02-15 | 2020-02-26 | 株式会社デンソー | Exhaust gas purification system |
WO2019121513A1 (en) | 2017-12-18 | 2019-06-27 | Intervet International B.V. | Swine influenza a virus vaccine |
US20230265130A1 (en) | 2020-06-19 | 2023-08-24 | Intervet Inc. | Swine influenza a virus vaccine comprising a nucleic acid construct having a specific order of genes |
WO2021255222A1 (en) | 2020-06-19 | 2021-12-23 | Intervet International B.V. | Swine influenza a virus vaccine comprising two distinct rna replicon particles |
US20230248817A1 (en) | 2020-06-19 | 2023-08-10 | Intervet Inc. | Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus |
WO2021255221A1 (en) | 2020-06-19 | 2021-12-23 | Intervet International B.V. | Swine influenza a virus vaccine comprising a nucleic acid construct encoding antigens of specific virus lineages |
WO2024068637A1 (en) | 2022-09-27 | 2024-04-04 | Intervet International B.V. | A method of culturing lawsonia intracellularis bacteria |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020050A1 (en) * | 1995-11-30 | 1997-06-05 | Daratech Pty. Ltd. | Therapeutic and diagnostic compositions |
WO2005011731A1 (en) * | 2003-07-25 | 2005-02-10 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0382271T3 (en) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoler as adjuvants in vaccines |
FR2649012B1 (en) | 1989-07-03 | 1991-10-25 | Seppic Sa | INJECTABLE MULTIPHASIC EMULSIONS |
US5885823A (en) | 1995-06-05 | 1999-03-23 | Nobl Laboratories, Inc. | Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
AU775323B2 (en) * | 1999-05-13 | 2004-07-29 | Agriculture Victoria Services Pty Ltd | Lawsonia derived gene and related hemolysin polypeptides, peptides and proteins and their uses |
EP1094070A3 (en) | 1999-10-22 | 2002-01-09 | Pfizer Products Inc. | Lawsonia intracellularis proteins, and related methods and materials |
AU9315101A (en) | 2000-09-29 | 2002-04-08 | Univ Arizona | Improved vaccines for proliferative ileitis and methods of making and using the same |
DK1219711T3 (en) | 2000-12-20 | 2006-09-25 | Intervet Int Bv | Lawsonia Intracellularis vaccine |
MXPA06008217A (en) | 2004-01-22 | 2007-05-23 | Intervet Int Bv | Lawsonia intracellularis subunit vaccines. |
KR20090051129A (en) * | 2004-04-05 | 2009-05-20 | 화이자 프로덕츠 인코포레이티드 | Microfluidized oil-in-water emulsions and vaccine compositions |
MX2007003400A (en) * | 2004-09-22 | 2008-03-04 | Glaxosmithkline Biolog Sa | Immunogenic composition. |
US20070212373A1 (en) | 2004-12-08 | 2007-09-13 | Akzo Nobel N.V. | Lawsonia Intracellularis 26 Kd Subunit Vaccine |
US8834891B2 (en) * | 2005-03-14 | 2014-09-16 | Boehringer Ingelheim Vetmedica, Inc. | Immunogenic compositions comprising Lawsonia intracellularis |
US8398994B2 (en) * | 2005-07-15 | 2013-03-19 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia vaccine and methods of use thereof |
AU2006289102C1 (en) | 2005-09-09 | 2017-11-30 | Intervet International B.V. | PCV-2 vaccine |
KR20080100384A (en) | 2006-03-03 | 2008-11-17 | 메리얼 리미티드 | Mycoplasma hyopneumoniae vaccine |
BRPI0710210A2 (en) * | 2006-03-30 | 2011-05-24 | Glaxomithkline Biolog S A | immunogenic composition, vaccine, methods for preparing the vaccine, and for preventing or treating staphylococcal infection, use of the immunogenic composition, and process for conjugating oligosaccharide or capsular polysaccharide |
US8021670B2 (en) | 2006-04-10 | 2011-09-20 | Intervet International B.V. | Vaccine against Mycoplasma PRRSV |
US8470336B2 (en) * | 2006-05-25 | 2013-06-25 | Boehringer Ingelheim Vetmedica, Inc. | Vaccination of young animals against Lawsonia intracellularis infections |
WO2007138036A1 (en) | 2006-05-30 | 2007-12-06 | Intervet International B.V. | Vaccine against rickettsia-like organisms |
TWI551295B (en) * | 2008-04-18 | 2016-10-01 | 英特威特國際股份有限公司 | Vaccine for protection against lawsonia intracellularis |
TWI449533B (en) | 2008-04-18 | 2014-08-21 | Intervet Int Bv | Vaccine for protection against lawsonia intracellularis, mycoplasma hyopneumoniae and porcine circo virus |
ES2800033T3 (en) | 2015-02-04 | 2020-12-23 | Intervet Int Bv | A vaccine to use against asymptomatic Lawsonia infection in a pig |
-
2009
- 2009-03-30 TW TW098110510A patent/TWI551295B/en active
- 2009-04-16 DK DK18154850.4T patent/DK3351267T3/en active
- 2009-04-16 BR BR122019000869-8A patent/BR122019000869B1/en active IP Right Grant
- 2009-04-16 CN CN2009801136792A patent/CN102006883A/en active Pending
- 2009-04-16 PL PL18154850T patent/PL3351267T3/en unknown
- 2009-04-16 EP EP09753743.5A patent/EP2268308B1/en active Active
- 2009-04-16 JP JP2011504462A patent/JP6026106B2/en active Active
- 2009-04-16 HU HUE09753743A patent/HUE038294T2/en unknown
- 2009-04-16 EP EP20167953.7A patent/EP3708186A1/en active Pending
- 2009-04-16 US US12/988,083 patent/US20110033496A1/en not_active Abandoned
- 2009-04-16 EP EP18154850.4A patent/EP3351267B1/en active Active
- 2009-04-16 WO PCT/EP2009/054516 patent/WO2009144088A2/en active Application Filing
- 2009-04-16 CA CA2717969A patent/CA2717969C/en active Active
- 2009-04-16 DK DK09753743.5T patent/DK2268308T3/en active
- 2009-04-16 PL PL09753743T patent/PL2268308T3/en unknown
- 2009-04-16 ES ES09753743.5T patent/ES2666671T3/en active Active
-
2012
- 2012-10-22 US US13/657,210 patent/US8597662B2/en active Active
-
2013
- 2013-07-17 US US13/944,234 patent/US9198963B2/en active Active
-
2015
- 2015-08-11 JP JP2015158693A patent/JP6138875B2/en active Active
-
2020
- 2020-11-25 HU HUS2000047C patent/HUS2000047I1/en unknown
-
2021
- 2021-01-18 FR FR21C1002C patent/FR21C1002I1/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020050A1 (en) * | 1995-11-30 | 1997-06-05 | Daratech Pty. Ltd. | Therapeutic and diagnostic compositions |
WO2005011731A1 (en) * | 2003-07-25 | 2005-02-10 | Boehringer Ingelheim Vetmedica, Inc. | Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8530223B2 (en) | 2009-11-09 | 2013-09-10 | Intervet International B.V. | Method to grow Lawsonia intracellularis bacteria in persistently infected McCoy cells |
KR101837768B1 (en) | 2011-05-25 | 2018-03-12 | 건국대학교 산학협력단 | Protein for dianosing porcine proliferative enteritis and application thereof |
RU2655615C1 (en) * | 2013-12-03 | 2018-05-29 | Интервет Интернэшнл Б.В. | Swine vaccine against prrs and lawsonia intracellularis |
WO2015082458A1 (en) | 2013-12-03 | 2015-06-11 | Intervet International B.V. | Vaccine against porcine circo virus type 2 |
WO2015082457A1 (en) | 2013-12-03 | 2015-06-11 | Intervet International B.V. | Vaccine against lawsonia intracellularis and porcine circovirus 2 |
EP3673916A1 (en) | 2013-12-03 | 2020-07-01 | Intervet International B.V. | Vaccine against lawsonia intracellularis and porcine circovirus2 |
US10130699B2 (en) | 2013-12-03 | 2018-11-20 | Intervet Inc. | Vaccine against Lawsonia intracellularis and porcine circovirus 2 |
RU2723022C2 (en) * | 2015-02-04 | 2020-06-08 | Интервет Интернэшнл Б.В. | Vaccine for use against subclinical lawsonia infection in pigs |
US10751405B2 (en) | 2015-02-04 | 2020-08-25 | Intervet Inc. | Vaccine for use against subclinical Lawsonia infection in a pig |
US10265392B2 (en) | 2015-02-04 | 2019-04-23 | Intervet Inc. | Vaccine for use against subclinical Lawsonia infection in a pig |
US20180021422A1 (en) * | 2015-02-04 | 2018-01-25 | Intervet Inc. | A vaccine for use against subclinical lawsonia infection in a pig |
WO2016124620A1 (en) | 2015-02-04 | 2016-08-11 | Intervet International B.V. | A vaccine for use against subclinical lawsonia infection in a pig |
RU2709197C2 (en) * | 2015-02-04 | 2019-12-17 | Интервет Интернэшнл Б.В. | Vaccine for use against subclinical infection lawsonia in pigs |
EP3253410B1 (en) | 2015-02-04 | 2020-05-06 | Intervet International B.V. | A vaccine for use against subclinical lawsonia infection in a pig |
EP3253409B1 (en) | 2015-02-04 | 2020-05-06 | Intervet International B.V. | A vaccine for use against subclinical lawsonia infection in a pig |
WO2016124623A1 (en) | 2015-02-04 | 2016-08-11 | Intervet International B.V. | A vaccine for use against subclinical lawsonia infection in a pig |
WO2019110481A1 (en) | 2017-12-04 | 2019-06-13 | Intervet International B.V. | Vaccination with replicon particles and oil adjuvant |
WO2019166362A1 (en) | 2018-02-28 | 2019-09-06 | Boehringer Ingelheim Vetmedica Gmbh | Method for reducing skatole and/or indole in animals |
US10792352B2 (en) | 2018-02-28 | 2020-10-06 | Boehringer Ingelheim Vetmedica Gmbh | Method for reducing skatole and/or indole in animals |
WO2023072805A1 (en) | 2021-10-25 | 2023-05-04 | Intervet International B.V. | A vaccine for the protection of piglets against swine influenza a virus infection |
WO2023073640A1 (en) | 2021-11-01 | 2023-05-04 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic gel compositions |
Also Published As
Publication number | Publication date |
---|---|
CA2717969C (en) | 2016-06-07 |
ES2666671T3 (en) | 2018-05-07 |
JP6026106B2 (en) | 2016-11-16 |
EP3351267A1 (en) | 2018-07-25 |
JP2011516600A (en) | 2011-05-26 |
DK2268308T3 (en) | 2018-05-22 |
PL3351267T3 (en) | 2020-11-30 |
US8597662B2 (en) | 2013-12-03 |
US20110033496A1 (en) | 2011-02-10 |
US20130045228A1 (en) | 2013-02-21 |
EP3708186A1 (en) | 2020-09-16 |
BRPI0909769A2 (en) | 2015-08-11 |
TWI551295B (en) | 2016-10-01 |
EP3351267B1 (en) | 2020-08-05 |
JP2016026154A (en) | 2016-02-12 |
FR21C1002I1 (en) | 2021-03-05 |
US20130302372A1 (en) | 2013-11-14 |
JP6138875B2 (en) | 2017-05-31 |
CA2717969A1 (en) | 2009-12-03 |
HUS2000047I1 (en) | 2020-12-28 |
PL2268308T3 (en) | 2018-07-31 |
DK3351267T3 (en) | 2020-09-21 |
HUE038294T2 (en) | 2018-10-29 |
EP2268308A2 (en) | 2011-01-05 |
TW201002342A (en) | 2010-01-16 |
WO2009144088A3 (en) | 2010-05-06 |
BR122019000869B1 (en) | 2023-11-07 |
CN102006883A (en) | 2011-04-06 |
EP2268308B1 (en) | 2018-03-14 |
US9198963B2 (en) | 2015-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9198963B2 (en) | Vaccine for protection against Lawsonia intracellularis | |
US9084768B2 (en) | Vaccine for protection against Lawsonia intracellularis, Mycoplasma hyopneumoniae and Porcine circo virus | |
JP2009501730A (en) | Lawsonia vaccine and method of use | |
RU2523561C2 (en) | Vaccine against lawsonia intracellularis | |
ES2802748T3 (en) | Vaccine for protection against Lawsonia intracellularis | |
BRPI0909769B1 (en) | USE OF A CARBOHYDRATE-CONTAINING INACTIVATED WHOLE CELL COMPOSITION OF LAWSONIA INTRACELLULARIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980113679.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09753743 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009753743 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2717969 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12988083 Country of ref document: US Ref document number: 2011504462 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201011792 Country of ref document: UA Ref document number: 2010146927 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0909769 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100930 |